Free Trial
NASDAQ:LGND

Ligand Pharmaceuticals (LGND) Stock Price, News & Analysis

Ligand Pharmaceuticals logo
$123.97 -1.01 (-0.81%)
As of 10:06 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Ligand Pharmaceuticals Stock (NASDAQ:LGND)

Key Stats

Today's Range
$123.06
$124.52
50-Day Range
$100.19
$124.98
52-Week Range
$90.29
$129.90
Volume
1,462 shs
Average Volume
115,033 shs
Market Capitalization
$2.39 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$147.17
Consensus Rating
Buy

Company Overview

Ligand Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
90th Percentile Overall Score

LGND MarketRank™: 

Ligand Pharmaceuticals scored higher than 90% of companies evaluated by MarketBeat, and ranked 105th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Ligand Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Ligand Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about Ligand Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Ligand Pharmaceuticals are expected to grow by 114.45% in the coming year, from $1.73 to $3.71 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Ligand Pharmaceuticals is -17.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Ligand Pharmaceuticals is -17.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Ligand Pharmaceuticals has a P/B Ratio of 2.82. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Ligand Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    6.41% of the float of Ligand Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Ligand Pharmaceuticals has a short interest ratio ("days to cover") of 9.7.
  • Change versus previous month

    Short interest in Ligand Pharmaceuticals has recently decreased by 6.50%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Ligand Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Ligand Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.41% of the float of Ligand Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Ligand Pharmaceuticals has a short interest ratio ("days to cover") of 9.7.
  • Change versus previous month

    Short interest in Ligand Pharmaceuticals has recently decreased by 6.50%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Ligand Pharmaceuticals has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Ligand Pharmaceuticals this week, compared to 6 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Ligand Pharmaceuticals insiders have bought 429.77% more of their company's stock than they have sold. Specifically, they have bought $1,156,542.00 in company stock and sold $218,310.00 in company stock.

  • Percentage Held by Insiders

    Only 7.00% of the stock of Ligand Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    91.28% of the stock of Ligand Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Ligand Pharmaceuticals' insider trading history.
Receive LGND Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

LGND Stock News Headlines

"I'm risking my reputation on this"
Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.
Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™
See More Headlines

LGND Stock Analysis - Frequently Asked Questions

Ligand Pharmaceuticals' stock was trading at $107.15 at the start of the year. Since then, LGND shares have increased by 15.7% and is now trading at $123.97.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) released its earnings results on Thursday, May, 8th. The biotechnology company reported $1.33 EPS for the quarter, beating the consensus estimate of $1.23 by $0.10. The biotechnology company earned $45.33 million during the quarter, compared to the consensus estimate of $37.84 million. Ligand Pharmaceuticals had a negative net margin of 73.07% and a negative trailing twelve-month return on equity of 7.83%.
Read the conference call transcript
.

Top institutional investors of Ligand Pharmaceuticals include Woodstock Corp (0.15%), CWC Advisors LLC. (0.02%) and Contravisory Investment Management Inc. (0.01%). Insiders that own company stock include John L Higgins, Todd C Davis, Matthew E Korenberg, John W Kozarich, Andrew Reardon, John L Lamattina, Stephen L Sabba, Octavio Espinoza and Nancy Ryan Gray.
View institutional ownership trends
.

Shares of LGND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Ligand Pharmaceuticals investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
5/08/2025
Today
7/10/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:LGND
CIK
886163
Employees
80
Year Founded
N/A

Price Target and Rating

High Price Target
$160.00
Low Price Target
$135.00
Potential Upside/Downside
+17.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($7.12)
Trailing P/E Ratio
N/A
Forward P/E Ratio
72.24
P/E Growth
N/A
Net Income
-$4.03 million
Net Margins
-73.07%
Pretax Margin
-88.77%
Return on Equity
-7.83%
Return on Assets
-6.92%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.27
Quick Ratio
5.02

Sales & Book Value

Annual Sales
$167.13 million
Price / Sales
14.43
Cash Flow
$1.64 per share
Price / Cash Flow
76.17
Book Value
$43.95 per share
Price / Book
2.84

Miscellaneous

Outstanding Shares
19,290,000
Free Float
17,943,000
Market Cap
$2.41 billion
Optionable
Optionable
Beta
0.84

Social Links

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:LGND) was last updated on 7/11/2025 by MarketBeat.com Staff
From Our Partners